LL-37 vs GHK-Cu: What Sets Them Apart

LL-37 and GHK-Cu are not variants of the same molecule: they belong to different peptide families and the literature studies them for different reasons. LL-37 is a 37-amino-acid, positively charged peptide from the cathelicidin family, studied for antimicrobial activity and its role in innate immunity. GHK-Cu is a tripeptide — glycine, histidine, lysine — bound to a copper ion, studied mainly in extracellular matrix remodeling and dermal signaling. They share the generic word "peptide" in search queries, but nothing else: not structure, not size, not mechanism.

What is LL-37?

LL-37 is the only cathelicidin family member identified in humans, derived from the precursor protein hCAP18. It is a 37-residue chain that, in solution, folds into an amphipathic alpha-helix — one hydrophobic face, one positively charged face. That geometry is the basis for the two most-cited research lines on the molecule: its interaction with microbial membranes and its modulating effect on innate immune cells, documented in reviews such as those indexed on PubMed on cationic antimicrobial peptides.

Because of its size — 37 residues is large for a research peptide — and its net positive charge, LL-37 behaves very differently in the lab than a short peptide does. It is more sensitive to proteolytic degradation, and its solubility depends heavily on the pH and ionic strength of the buffer used.

What is GHK-Cu?

GHK-Cu is something else entirely: a tripeptide with the sequence Gly-His-Lys that forms a coordination complex with a copper ion (Cu²⁺). It was first described as a natural component of human plasma whose concentration declines with age, and since then the literature has studied it mainly in the context of collagen remodeling and copper-dependent cell signaling in dermal tissue.

Unlike LL-37, GHK-Cu is a small, stable molecule, and its biological activity depends on the copper ion being retained at the histidine-copper coordination site. If that coordination breaks, the peptide no longer behaves the same way in assays — one reason a batch's certificate of analysis matters as much for GHK-Cu as for any other compound in a catalogue. PeptoClinic quotes GHK-Cu as lyophilized research material, with the lab report for the batch (task 204977, analyzed by Janoshik Analytical) available on request.

The structural differences, plainly

• Size: LL-37 has 37 residues; GHK-Cu has 3, plus a coordinated metal ion.
• Charge: LL-37 is cationic along its whole length; GHK-Cu's charge is concentrated at the copper-binding site.
• Conformation: LL-37 depends on folding into an alpha-helix to be active; GHK-Cu needs no secondary folding — its activity depends on copper coordination.
• Stability: the copper-bound tripeptide tends to be more stable against degradation than a 37-residue chain exposed to proteases.

The mechanistic differences the literature studies

Research on LL-37 concentrates on two axes: direct interaction with bacterial lipid membranes (hence the "antimicrobial" interest) and modulation of innate immune response — cell recruitment, surface-receptor signaling. It is a peptide that acts mainly through physical interaction with biological structures and through immune signaling.

Research on GHK-Cu concentrates on copper-dependent signaling: the complex participates as a cofactor in enzymatic processes linked to collagen synthesis and remodeling, and to fibroblast response in tissue-repair models. It does not act by breaking membranes; it acts as part of a metal-dependent signaling cascade.

In other words, these are two research subjects that share the generic label "peptide" but that an immunologist and a dermal biologist would approach with entirely different questions.

Which research lines does each appear in today?

LL-37 appears mostly in studies of antimicrobial resistance, epithelial barrier immunology, and infection models. It is frequently mentioned alongside other endogenous antimicrobial peptides in reviews of innate host defense.

GHK-Cu appears in studies of extracellular matrix, dermal signaling, and tissue-repair models — territory where PeptoClinic's catalogue also carries other compounds of interest for the same kind of research, such as BPC-157 or KPV, each with its own proposed mechanism in the literature and its own purity report.

How purity is documented in each case

PeptoClinic publishes the laboratory report for every batch it distributes, and the lowest purity published so far across those reports is 99.669%, corresponding to the MOTS-c batch analyzed by Janoshik Analytical — that figure is cited deliberately, not the highest one, because it is the real floor a researcher can expect to see, not the best-case scenario. The quality page explains how to read a full certificate of analysis: which columns to check, what the chromatogram area percentage means, and why a report with no date or task number proves nothing.

The framework this operates within

All material PeptoClinic quotes is supplied strictly for Research Use Only (RUO): in vitro and laboratory assays. Nothing on this site is a medicine, a supplement, or a food; nothing is approved or intended for human or veterinary consumption, diagnosis, or treatment, and none of these statements have been evaluated by the FDA, ANMAT, or any equivalent authority. No prescription is written or filled, and questions about administration in people are declined.